Abstract

<h3>Objectives</h3> We sought to determine potential differences in the humoral immune response to herpes simplex virus type 1 (HSV-1) in patients after primary infection in either oral or genital sites. <h3>Methods</h3> Serum samples from 20 patients with primary HSV-1 infection (10 oral, 10 genital) were compared. A neutralization assay categorized samples by their ability to inhibit virus entry into cells. An enzyme-linked immunosorbent assay determined the quantity of antibodies against each of the major HSV-1 glycoproteins (gD, gB, gC, gH/gL). Surface plasmon resonance imaging (SPRi) was used to estimate the quality of the response by determining the epitope specificity of antibodies against the receptor-binding glycoprotein gD. Information from these assays was combined to develop a comprehensive profile of immunologic response to HSV-1 infection. <h3>Results</h3> All 10 oral site serum samples contained significant levels of virus-specific antibodies to block virus entry and demonstrated excellent immune response to the major virion glycoproteins. In contrast, only 4 of the 10 genital site serum samples were able to block virus entry. The 6 genital site sera that failed to block entry had markedly reduced antiglycoprotein antibody levels, indicating a poor overall HSV-1 immunologic response. The quantity of antiglycoprotein antibodies in the 4 genital (protective) sera mirrored that induced by oral infection. Subsequently, SPRi was used to determine whether the qualitative response was equivalent between the oral and genital site sera. All 10 oral site sera targeted gD epitopes at levels significantly higher and more varied than those generated for the 4 protective genital site samples. Interestingly, the gD epitope profiles of the 6 nonprotective genital site samples were directed at a single non-neutralizing antigenic site on gD that is involved in cell-to-cell spread. <h3>Conclusions</h3> Based on a comprehensive profile of immunologic response to HSV-1 infection for individuals infected at either oral or genital sites, results of this study suggest that the site of primary infection is important in driving the overall humoral immune-protective response. Findings of this study will have direct implications for the future development of a glycoprotein-epitope–based HSV-1 vaccine.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call